行情

AMRN

AMRN

阿玛琳
NASDAQ

实时行情|Nasdaq Last Sale

5.78
+0.06
+0.96%
交易中 14:20 03/05 EST
开盘
5.82
昨收
5.72
最高
6.00
最低
5.35
成交量
687.01万
成交额
--
52周最高
16.24
52周最低
3.360
市值
22.73亿
市盈率(TTM)
-113.9053
分时
5日
1月
3月
1年
5年
每日生物技术动向:默克去购物,莎瑞达公司的决策日,辉瑞公司,Moderna公布冠状病毒变种的疫苗策略
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 02/25 13:08
8-K:AMARIN CORP PLC \英国
(EDGAR Online via COMTEX) -- AMARIN CORP PLC\UK 00-0000000 false 0000897448 0000897448 2021-02-25 2021-02-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/25 12:12
Amarin Corp Q4 EPS $ 0.04 Beats($ 0.01)估计,销售额$ 167.30M Beat $ 164.94M估计
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.01) by 500 percent. This is a 100 percent increase over earnings of $0.02 per share from the same
Benzinga · 02/25 10:59
2020年血脂异常药物市场:行业报告,趋势,到2027年的份额和预测
Japan, Japan, Tue, 23 Feb 2021 06:18:04 / Comserve Inc. / -- Competitive Analysis: AstraZeneca, Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin...
Comserve · 02/23 11:19
生物技术的一周提前:强生疫苗Adcom会议,Sarepta FDA决定和大量收入
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week.
Benzinga · 02/20 14:36
Amarin宣布其在中国的企业合作伙伴Edding已将VASCEPQA推进到中国内地和香港的监管审查流程中
Amarin Corporation plc (NASDAQ:AMRN) today announced that its corporate partner in China, Edding, has progressed VASCEPA® (icosapent ethyl) into commencement of the regulatory review processes in Mainland China and
Benzinga · 02/09 12:02
Amarin的首席科学官正在行使期权
Yesterday it was reported that the Chief Scientific Officer of Amarin (AMRN), Steven B Ketchum, exercised options to sell 217,728 AMRN shares for a total
SmarterAnalyst · 02/05 08:00
分析家的热门医疗保健精选:Amarin(AMRN),Taro Pharmaceutical(TARO)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amarin (AMRN), Taro Pharmaceutical (TARO) and VYNE
SmarterAnalyst · 02/01 11:25
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解AMRN最新的财务预测,通过AMRN每股收益,每股净资产,每股现金流等数据分析阿玛琳近期的经营情况,然后做出明智的投资选择。
分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测AMRN价格均价为10.64,最高价位19.00,最低价为6.00。
EPS
机构持股
总机构数: 494
机构持股: 2.03亿
持股比例: 51.51%
总股本: 3.94亿
类型机构数股数
增持
43
2,882.26万
建仓
92
-1,358.38万
减持
84
1,397.22万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.01%
制药与医学研究
+0.52%
高管信息
Non-Executive Chairman/Independent Director
Lars Ekman
President/Chief Executive Officer/Director
John Thero
Chief Financial Officer/Senior Vice President/Assistant Secretary
Michael Kalb
Executive Vice President/General Counsel/Secretary
Joseph Kennedy
Senior Vice President/Chief Scientific Officer
Stephen Ketchum
Senior Vice President
Aaron Berg
Non-Executive Independent Director
Patrick O'Sullivan
Non-Executive Independent Director
Kristine Peterson
Non-Executive Independent Director
David Stack
Other
Craig Granowitz
Non-Executive Independent Director
Jan van Heek
Non-Executive Independent Director
Joseph Zakrzewski
Non-Executive Independent Director
G. van Heek
暂无数据
AMRN 简况
Amarin Corporation plc是一家在脂质科学领域开展业务并致力于商业化与开发心血管健康疗法的生物制药公司。该公司的主导产品Vascepa(二十碳五烯酸乙酯)胶囊已被美国食品和药物管理局(FDA)批准用作膳食辅助剂,用于降低严重高甘油三酯血症成年患者的甘油三酯水平。该公司主要从事Vascepa的开发与商业化。Vascepa的适应症,被称为MARINE适应症,主要根据在所批准服用的患者群体中对Vascepa进行MARINE研究的结果得出。该公司主要向批发商、选定区域批发商和专业药物供应商(或统称为将Vascepa转售给零售药房以转售给患者与医疗机构的分销商)销售Vascepa。该公司在美国市场销售Vascepa。

微牛提供Amarin Corporation plc (ADR)(NASDAQ-AMRN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的AMRN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AMRN股票基本功能。